Jiangxi Cancer Hospital ( Site 3313)

Nanchang, Jiangxi 330029

0 studies enrolling now · 1 studies all time

What they study most

Head and Neck Squamous Cell Carcinoma

Studies at this site

• A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) — Completed